middle.news

How Dimerix’s US$30M Amicus Deal Could Transform Kidney Disease Treatment

8:44am on Friday 25th of July, 2025 AEST Healthcare
Read Story

How Dimerix’s US$30M Amicus Deal Could Transform Kidney Disease Treatment

8:44am on Friday 25th of July, 2025 AEST
Key Points
  • Exclusive US license deal with Amicus Therapeutics for DMX-200
  • Up to US$590 million in upfront, milestone payments, and royalties
  • Over AU$65 million received from four licensing deals to date
  • FDA accepts proteinuria as primary endpoint for US approval
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Dimerix (ASX:DXB)
OPEN ARTICLE